VIA
CRBP icon

Vident Investment Advisory’s Corbus Pharmaceuticals CRBP Stock Holding History

Vident Investment Advisory’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-8,920
Closed -$67K – 1151
2022
Q2 		$67K Buy
8,920
+415
+5% +$4.01K ﹤0.01% 1224
2022
Q1 		$135K Buy
8,505
+3,389
+66% +$44.9K ﹤0.01% 1219
2021
Q4 		$95K Buy
5,116
+212
+4% +$5.74K ﹤0.01% 1181
2021
Q3 		$150K Buy
+4,904
New +$193K ﹤0.01% 1110

Other funds holding CRBP

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vident Investment Advisory's CRBP Position: Q3 2022 in Review

Vident Investment Advisory sold out of Corbus Pharmaceuticals (CRBP) in Q3 2022, closing a stake of 8,920 shares — an estimated $67K sold.

Vident Investment Advisory first reported a position in CRBP in Q3 2021 and held it in 4 quarters. The position peaked at $150K in Q3 2021. 64 funds tracked by Wall St. Rank hold CRBP as of Q3 2022.

  • Vident Investment Advisory reported no remaining Corbus Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Vident Investment Advisory sold 8,920 Corbus Pharmaceuticals shares in Q3 2022, an estimated $67K.
  • Vident Investment Advisory first reported a position in Corbus Pharmaceuticals in Q3 2021 and held it in 4 quarters.
  • Vident Investment Advisory's Corbus Pharmaceuticals position peaked at $150K in Q3 2021.
  • 64 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2022.

Based on Vident Investment Advisory's 13F filing for Q3 2022, filed 14 Nov 2022.